International Assets Investment Management LLC Purchases 66,345 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

International Assets Investment Management LLC boosted its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 11,244.9% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 66,935 shares of the medical equipment provider’s stock after buying an additional 66,345 shares during the period. International Assets Investment Management LLC’s holdings in Zimmer Biomet were worth $8,146,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. increased its position in Zimmer Biomet by 19.0% in the 1st quarter. Vanguard Group Inc. now owns 23,102,761 shares of the medical equipment provider’s stock valued at $2,954,843,000 after buying an additional 3,695,510 shares in the last quarter. American Century Companies Inc. increased its position in Zimmer Biomet by 21.2% in the 3rd quarter. American Century Companies Inc. now owns 4,863,741 shares of the medical equipment provider’s stock valued at $545,809,000 after buying an additional 852,186 shares in the last quarter. Geode Capital Management LLC increased its position in Zimmer Biomet by 2.3% in the 1st quarter. Geode Capital Management LLC now owns 4,315,167 shares of the medical equipment provider’s stock valued at $556,244,000 after buying an additional 96,028 shares in the last quarter. Morgan Stanley increased its position in Zimmer Biomet by 80.5% in the 4th quarter. Morgan Stanley now owns 3,102,429 shares of the medical equipment provider’s stock valued at $395,560,000 after buying an additional 1,384,068 shares in the last quarter. Finally, Victory Capital Management Inc. increased its position in Zimmer Biomet by 4.9% in the 3rd quarter. Victory Capital Management Inc. now owns 3,080,463 shares of the medical equipment provider’s stock valued at $345,690,000 after buying an additional 144,147 shares in the last quarter. 88.89% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on ZBH. JPMorgan Chase & Co. lifted their price target on Zimmer Biomet from $115.00 to $125.00 and gave the company a “neutral” rating in a research note on Friday, February 9th. Citigroup lifted their price target on Zimmer Biomet from $134.00 to $140.00 and gave the company a “neutral” rating in a research note on Wednesday, April 3rd. TheStreet upgraded Zimmer Biomet from a “c” rating to a “b-” rating in a research note on Thursday, February 8th. Raymond James lifted their price target on Zimmer Biomet from $133.00 to $137.00 and gave the company an “outperform” rating in a research note on Wednesday, January 3rd. Finally, StockNews.com downgraded Zimmer Biomet from a “strong-buy” rating to a “buy” rating in a research note on Monday, February 19th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat, Zimmer Biomet has a consensus rating of “Hold” and an average target price of $139.39.

Insider Buying and Selling at Zimmer Biomet

In other Zimmer Biomet news, VP Chad F. Phipps sold 26,156 shares of the business’s stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $128.62, for a total transaction of $3,364,184.72. Following the sale, the vice president now owns 44,145 shares of the company’s stock, valued at approximately $5,677,929.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.95% of the company’s stock.

Zimmer Biomet Trading Down 2.4 %

NYSE:ZBH opened at $124.48 on Friday. The company has a current ratio of 1.61, a quick ratio of 0.78 and a debt-to-equity ratio of 0.39. The stock has a market capitalization of $25.58 billion, a PE ratio of 25.46, a price-to-earnings-growth ratio of 2.34 and a beta of 1.01. The firm’s 50 day moving average is $126.73 and its 200 day moving average is $118.88. Zimmer Biomet Holdings, Inc. has a 12 month low of $102.00 and a 12 month high of $149.25.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Thursday, February 8th. The medical equipment provider reported $2.20 EPS for the quarter, topping analysts’ consensus estimates of $2.15 by $0.05. The company had revenue of $1.94 billion for the quarter, compared to analysts’ expectations of $1.93 billion. Zimmer Biomet had a net margin of 13.85% and a return on equity of 12.79%. Zimmer Biomet’s revenue was up 6.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.88 EPS. Sell-side analysts expect that Zimmer Biomet Holdings, Inc. will post 8.07 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, April 30th. Shareholders of record on Friday, March 29th will be issued a dividend of $0.24 per share. The ex-dividend date is Wednesday, March 27th. This represents a $0.96 dividend on an annualized basis and a yield of 0.77%. Zimmer Biomet’s payout ratio is 19.63%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.